- ELDN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Eledon Pharmaceuticals (ELDN) CORRESPCorrespondence with SEC
Filed: 30 Jul 18, 12:00am
Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, California 92612
(949)238-8090
July 30, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Irene Paik
Re: | Novus Therapeutics, Inc. |
Registration Statement on Form S-3
Filed July 23, 2018
FileNo. 333-226286
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on FormS-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Daylight Time, on, July 31, 2018 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours, |
Novus Therapeutics, Inc. |
/s/ Gregory J. Flesher |
Gregory J. Flesher |
Chief Executive Officer |
cc: | Ryan A. Murr, Gibson, Dunn & Crutcher LLP |